^
    Apply
    Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas (NCT04750928)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/29/2021
    Primary completion :
    12/31/2028
    Completion :
    12/31/2029
    NF1
    |
    NF1 mutation
    |
    Verzenio (abemaciclib)
    Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation (ELAINE 3) (NCT05696626)
    Phase 3
    Sermonix Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/31/2023
    Primary completion :
    04/01/2027
    Completion :
    04/01/2028
    ER
    |
    ESR1 mutation
    |
    Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)
    An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (NCT05952557)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/05/2023
    Primary completion :
    03/04/2030
    Completion :
    05/06/2037
    HER-2 • ER
    |
    HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)
    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) (NCT05563220)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/24/2023
    Primary completion :
    12/27/2026
    Completion :
    12/28/2028
    HER-2 • ER • PIK3CA • CDK4
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)
    A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence (CAROLEEN) (NCT06830720)
    Phase N/A
    Novartis Pharmaceuticals
    Not yet recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/09/2025
    Primary completion :
    05/31/2030
    Completion :
    05/31/2030
    HER-2
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • Kisqali (ribociclib)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (MORPHEUS BC) (NCT04802759)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/22/2021
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    ER • CDK4
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (GDC-9545) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703)
    Phase 1/2
    Multiple Myeloma Research Consortium
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    04/01/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRAF • SLC1A5
    |
    Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623
    Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII) (NCT04432454)
    Phase 2
    Sermonix Pharmaceuticals Inc.
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    09/29/2020
    Primary completion :
    01/28/2025
    Completion :
    01/28/2025
    HER-2 • ER
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • Fablyn (lasofoxifene)
    Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) (NCT05386108)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/31/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • Orserdu (elacestrant)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-TNBC) (NCT03424005)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/30/2018
    Primary completion :
    05/03/2028
    Completion :
    05/03/2028
    HER-2 • PD-L1 • PIK3CA
    |
    PD-L1 expression • PIK3CA mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) (NCT04961996)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/27/2021
    Primary completion :
    03/31/2026
    Completion :
    11/21/2033
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • giredestrant (GDC-9545)
    A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) (NCT06065748)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    12/11/2023
    Primary completion :
    07/30/2026
    Completion :
    12/30/2028
    HER-2 • ER • CDK4
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (GDC-9545)
    Study of AVZO-021 in Patients with Advanced Solid Tumors (ARTS-021-1001) (NCT05867251)
    Phase 1/2
    Avenzo Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/30/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2030
    HER-2 • CCNE1
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021
    Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss (NCT06810544)
    Phase 1/2
    Tango Therapeutics, Inc.
    Not yet recruiting
    Last update posted :
    02/05/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/31/2027
    Completion :
    09/30/2027
    MTAP
    |
    Verzenio (abemaciclib)
    Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (NCI-2022-04099) (NCT05372640)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/10/2023
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    NUTM1
    |
    Verzenio (abemaciclib) • ZEN-3694
    Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma (NCT06025747)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/09/2025
    Primary completion :
    03/03/2025
    Completion :
    03/03/2026
    MDM2 • CDK4
    |
    CDK4 amplification
    |
    Verzenio (abemaciclib)
    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/17/2020
    Primary completion :
    06/22/2023
    Completion :
    07/16/2025
    HER-2 • ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PGR positive
    |
    Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases (MCC-20899) (NCT04923542)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    11/30/2021
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
    Phase 1/2
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    07/19/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
    A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (KEYNOTE 287) (NCT02779751)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    11/14/2016
    Primary completion :
    02/03/2020
    Completion :
    12/01/2025
    HER-2 • PD-L1 • KRAS
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Verzenio (abemaciclib) • anastrozole
    A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) (NCT04975308)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    10/04/2021
    Primary completion :
    06/24/2024
    Completion :
    08/01/2027
    HER-2 • ER
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • exemestane • Inluriyo (imlunestrant)
    A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) (NCT04188548)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/22/2025
    Initiation :
    12/10/2019
    Primary completion :
    06/29/2020
    Completion :
    12/01/2027
    ER
    |
    HER-2 negative • EGFR positive
    |
    Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)
    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas (A071401) (NCT02523014)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    09/28/2015
    Primary completion :
    01/01/2026
    Completion :
    01/01/2028
    PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3
    |
    PIK3CA mutation • PTEN mutation
    |
    Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
    Genetic Testing in Guiding Treatment for Patients with Brain Metastases (NCT03994796)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    10/17/2019
    Primary completion :
    10/01/2026
    Completion :
    06/01/2028
    KRAS • BRAF • ER • PGR • ROS1 • NTRK
    |
    HER-2 positive • EGFR mutation • HER-2 negative
    |
    Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)
    A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) (NCT05307705)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    10/26/2024
    Initiation :
    05/11/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    HER-2 • ER • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant) • LOXO-783
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer (ONCO-Adher) (NCT06650423)
    Phase N/A
    Erika Matos
    Not yet recruiting
    Last update posted :
    10/21/2024
    Initiation :
    10/20/2024
    Primary completion :
    10/01/2025
    Completion :
    03/01/2026
    HER-2
    |
    HER-2 negative
    |
    Verzenio (abemaciclib)
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (NCT02977780)
    Phase 2
    Patrick Wen, MD
    Recruiting
    Last update posted :
    10/17/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/01/2027
    Completion :
    04/30/2027
    IDH1
    |
    IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S
    Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer (NCT04481113)
    Phase 1
    OHSU Knight Cancer Institute
    Active, not recruiting
    Last update posted :
    10/17/2024
    Initiation :
    06/07/2021
    Primary completion :
    10/11/2023
    Completion :
    12/30/2025
    HER-2 • ER • PGR
    |
    Verzenio (abemaciclib) • Zejula (niraparib)
    A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (NCT02057133)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    08/28/2024
    Initiation :
    03/10/2014
    Primary completion :
    03/15/2021
    Completion :
    12/01/2024
    HER-2 • CDK4 • CDK6
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide
    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (NCT04931342)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    10/07/2021
    Primary completion :
    05/30/2028
    Completion :
    12/31/2028
    ER
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
    RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (NCT03675893)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/24/2018
    Primary completion :
    08/01/2026
    Completion :
    08/01/2029
    ER
    |
    ER positive
    |
    Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)
    Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (NCT04469764)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/16/2020
    Primary completion :
    07/01/2025
    Completion :
    07/01/2026
    CDK4
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    ETHAN - ET for Male BC (NCT05501704)
    Phase 2
    Jose Pablo Leone
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/11/2023
    Primary completion :
    04/01/2026
    Completion :
    04/01/2036
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (NCT05524584)
    Phase 2
    University of California, Irvine
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    08/31/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2028
    PGR
    |
    Verzenio (abemaciclib) • fulvestrant • anastrozole
    TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (C4891006) (NCT05548127)
    Phase 1/2
    Pfizer
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    02/23/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • vepdegestrant (ARV-471)
    A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS) (NCT03280563)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    12/26/2017
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2 • PD-L1
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (NCT04862663)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    05/10/2021
    Primary completion :
    11/01/2027
    Completion :
    08/14/2029
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR expression
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib)
    Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer (NCT04633239)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    07/02/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • HRD • CCNE1 • BRCA • CASP3
    |
    HRD
    |
    Lynparza (olaparib) • Verzenio (abemaciclib)
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (NCT04964934)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    06/30/2021
    Primary completion :
    04/25/2025
    Completion :
    11/26/2027
    HER-2 • ER
    |
    ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (NCT02791334)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/29/2016
    Primary completion :
    05/22/2020
    Completion :
    07/01/2024
    HER-2 • ER • PGR • MSI
    |
    MSI-H/dMMR • HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367